It has been downgraded to Neutral rating by Goldman Sachs, with a target price of $55.60 - just based on valuation grounds rather than anything fundamental. Probably reasonable, but nothing for long term holders to be concerned about.
- Forums
- ASX - By Stock
- Smashed 60 bucks n a matter of seconds ...
It has been downgraded to Neutral rating by Goldman Sachs, with...
Featured News
Add PME (ASX) to my watchlist
(20min delay)
|
|||||
Last
$187.14 |
Change
0.510(0.27%) |
Mkt cap ! $19.55B |
Open | High | Low | Value | Volume |
$187.80 | $189.57 | $186.01 | $50.17M | 268.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 688 | $186.50 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$187.80 | 1458 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 688 | 186.500 |
1 | 688 | 186.250 |
4 | 3401 | 186.000 |
2 | 2642 | 185.760 |
1 | 418 | 185.580 |
Price($) | Vol. | No. |
---|---|---|
188.000 | 640 | 1 |
188.130 | 688 | 1 |
188.290 | 23 | 1 |
188.380 | 784 | 2 |
188.630 | 688 | 1 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
PME (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online